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via mitochondrial-dependent actions of p53
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Abstract 
Background: Etoposide has been used clinically in cancer treatment, as well as in numerous research studies, for 
many years. However, there is incomplete information about its exact mechanism of action in induction of cell death.
Methods: Etoposide was compared at various concentrations to characterize the mechanisms by which it induces 
cell death. We investigated its effects on mouse embryonic fibroblasts (MEFs) and focused on both transcriptional and 
non‑transcriptional responses of p53.
Results: Here we demonstrate that treatment of MEFs with higher concentrations of etoposide induce apoptosis 
and activate the transcription‑dependent functions of p53. Interestingly, lower concentrations of etoposide also 
induced apoptosis, but without any evidence of p53‑dependent transcription up‑regulation. Treatment of MEFs with 
an inhibitor of p53, Pifithrin‑α, blocked p53‑dependent transcription but failed to rescue the cells from etoposide‑
induced apoptosis. Treatment with PES, which inhibits the mitochondrial arm of the p53 pathway inhibited etopo‑
side‑induced cell death at all concentrations tested.
Conclusions: We have demonstrated that transcriptional functions of p53 are dispensable for etoposide‑induced cell 
death. The more recently characterized effects of p53 at the mitochondria, likely involving its interactions with BCL‑2 
family members, are thus more important for etoposide’s actions.
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Background
p53 is recognized as the ‘guardian of the genome’, as its 
deficiency can lead to high frequency of cancer develop-
ment in both mice and men due to loss of chromosome 
integrity [1]. The basal levels of p53 are held in check by 
binding to an E3 ligase Mdm2 (Hdm2 in humans) which 
promotes degradation of the protein [1]. In response to 
acute stress the interaction between Mdm2 and p53 
decreases and levels of p53 are stabilized. Accumulation 
of p53 occurs predominantly in the nucleus where p53 
binds to specific DNA sequences and alters the transcrip-
tion of responsive genes [2]. Many p53 responsive genes 
are involved in the regulation of cell cycle, induction of 
apoptosis, or encode DNA repair enzymes. The altered 
activity of p53 responsive genes determines the outcome 
of the cell’s response to stress.
The death-inducing functions of p53 are tumour sup-
pressive, due to its ability to induce apoptosis to eliminate 
damaged cells. Apoptosis is initiated by the permeabi-
lization of the outer mitochondrial membrane, which 
is regulated by the members of BCL-2 family. The best 
characterized role of p53 in this context is as a nuclear 
transcription factor where it up-regulates the transcrip-
tion of several pro-apoptotic members of the BCL-2 
family, including BAX, PUMA, NOXA and BID, and 
inhibits the transcription of some anti-apoptotic mem-
bers such as BCL-2 and BCL-XL [3–6]. However, p53 can 
also induce apoptosis independently of its transcriptional 
function. Several apoptotic stimuli lead to the accumula-
tion of p53 in the cytoplasm and the mitochondria are 
increasingly recognised as novel sites for this p53 activity. 
Although the complete physiological relevance of tran-
scription-independent functions of p53 is not clear, they 
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have been shown to deliver a decisive signal for apoptosis 
to commence [7, 8]. p53 has also been shown to function 
by direct interactions with, or activation of, BCL-2 family 
proteins at the mitochondria [9, 10].
Conventional cancer therapies, including genotoxic 
drugs and ionizing radiation, induce DNA damage and 
consequently activate and stabilize p53 (reviewed in 
[11]). The therapeutic value of p53 activation by such 
drugs is severely mitigated by p53’s role in causing the 
harmful side effects observed as a result of radiation and 
chemotherapy. Strategies that allow a short term block-
age of p53 action in normal cells, while treating the p53 
deficient tumors, therefore appear to be reasonably 
appealing in reducing the adverse effects of cancer thera-
pies [1]. Two classes of small molecule inhibitors of p53 
named pifithrin (PFT) have been identified, which tar-
get either the transcriptional or the mitochondrial activ-
ity of p53 [12, 13]. While PFT-α prevents p53 mediated 
transcriptional activation and subsequent apoptosis [12], 
PFT-µ, also known as 2-phenylethynesulfonamide or 
PES, and shown to have effects on HSP70 [14], was dem-
onstrated to selectively inhibit the mitochondrial arm of 
p53 pathway by reducing the binding affinity of p53 to 
BCL-2 or BCL-XL [13]. Both drugs can offer some pro-
tection against a lethal dose of ionizing radiation.
Etoposide is a widely used drug for chemotherapy 
that induces DNA damage by inhibition of Topoi-
somerase II [15]. Ensuing DNA damage response 
involves cell cycle arrest and DNA repair, but eventu-
ally cell death if repair is unsuccessful. Etoposide-treated 
cells accumulate at G2/M, which can occur in both 
p53-dependent and -independent pathways [16]. In the 
p53-independent pathway the cell cycle block induced by 
DNA damage is controlled by ATM/ATR protein kinases. 
The p53-dependent pathway on the other hand achieves 
the arrest at G2 by p53 mediated repression of cyclin B1/
CDK1 promoters.
Despite the long history of studies investigating p53 
and cell death by chemotherapy drugs such as etoposide, 
there remain a number of questions regarding the mech-
anism by which these processes are regulated. Previously, 
we found that etoposide can have differential effects on 
DNA damage response pathways when used at higher or 
lower concentrations [17]. The aim of this study was to 
probe the cellular and molecular events regulated by dif-
ferent concentrations of etoposide. We show that 1.5 µM 
of etoposide, a clinically relevant concentration shown to 
be achieved in the plasma of responders [18–20], clearly 
induces apoptosis through the transcription-independent 
p53 mitochondrial pathway. Even at higher concentra-
tions of etoposide, where transcriptional activation via 
p53 occurs, our evidence suggests that the mitochon-
drial actions of p53 are more important for induction 
of cell death. These results may have implications in 
any attempts to modulate p53 function in the context of 
chemotherapy treatments.
Results and discussion
Etoposide increased the numbers of cells with sub‑G1 DNA 
content in a concentration‑dependent manner
In our previous studies we have investigated the role of 
MCL-1 in DNA damage response by using a low con-
centration of etoposide [17, 21]. To further our under-
standing of the differences in the cellular responses to 
treatment with low compared to high concentrations 
of etoposide, mouse embryo fibroblasts (MEFs) were 
treated with etoposide at different concentrations and 
analyzed for their apoptotic response after 18  h. Treat-
ment of MEFs with etoposide induced cell death, which 
was verified by the appearance of sub-diploid G1 peaks 
in flow cytometry analysis of permeabilized cells stained 
with propidium iodide. As shown in Fig.  1a, approxi-
mately 22% cells underwent apoptosis following treat-
ment with 1.5 µM etoposide for 18 h, compared to 60% 
with 15  µM and 65% with 150  µM etoposide. A repre-
sentative experiment showing the raw data from flow 
cytometry is shown in Additional file 1: Figure S1.
We next investigated the activation of caspase-3 in 
response to different concentrations of etoposide. West-
ern blot analysis with caspase-3 antibody showed that 
150  µM of etoposide induces robust cleavage of cas-
pase-3 within 6 h while 1.5 or 15 µM activate caspase-3 
only after 18 h (Fig. 1b). These results confirm that a low 
concentration of etoposide (1.5  µM) is indeed able to 
induce apoptosis in MEFs following treatment for less 
than 24 h. Thus, these conditions were subsequently used 
to compare effects of etoposide in inducing measurable 
cell death, allowing us to more carefully query any differ-
ences in the molecular responses to the various concen-
trations of drug.
Low or high concentrations of etoposide have different 
effects on transcriptional regulation by p53
Tumor suppressor protein p53 plays an important role in 
DNA damage-induced apoptosis, at least partly by acting 
as a transcription factor to direct the expression of apop-
totic mediators. We investigated the effect of etoposide 
on two representative transcriptional targets of p53, the 
BH3-only pro-apoptotic protein PUMA and cell cycle 
inhibitor p21CIP1/WAF1. Our results showed that treatment 
of cells with 15  µM of etoposide induced up-regulation 
of PUMA protein expression (known to be directly cor-
related with its p53-dependent transcription) within 1 h, 
which increased further at 3 and 6  h, before declining 
after 18 h (Fig. 2a, upper panel). A similar increase was 
observed in p21CIP1/WAF1 mRNA levels, which showed 
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an increase at 30 min and remained elevated even after 
18 h incubation (Fig. 2b, upper panel). When cells were 
treated similarly with 1.5  µM etoposide, which can still 
induce substantial cell killing, no increase in the expres-
sion of either PUMA protein or p21CIP1/WAF1 mRNA lev-
els was observed over the same time periods (Fig. 2a, b, 
lower panels). These results suggested that the cell death 
observed in response to treatment with 1.5  µM etopo-
side was independent of these two transcriptional events 
mediated by p53.
PFT‑α failed to rescue the cells from etoposide‑induced 
apoptosis
To determine whether higher concentrations of etopo-
side may be inducing apoptosis through the tran-
scription-dependent actions of p53, we used the small 
molecule inhibitor PFT-α. PFT-α has been shown to 
interfere with the expression of p53-inducible genes 
[12, 22, 23]. Although originally identified as a selective 
inhibitor of p53-induced transcription, it is now known 
to have other p53 independent functions [24]. Pre-treat-
ment of cells with 30 µM PFT-α, followed by 18 h treat-
ment with either 1.5 or 15 or 150 µM of etoposide failed 
to rescue the cells from DNA damage-induced apoptosis 
(Fig.  3a). In parallel experiments, cells were pre-treated 
with PFT-α and subsequently exposed to UVC radiation 
to induce DNA damage mediated apoptosis. PFT-α simi-
larly failed to exert any effect on UV treatment–induced 
apoptosis.
The inability of PFT-α to rescue cells treated with any 
concentration of etoposide or exposure to UV radiation 
was intriguing. We therefore confirmed the efficacy of 
Fig. 1 Concentration‑dependent etoposide‑induced apoptosis. a 
Flow cytometry analysis of MEFs was performed to determine the 
percentage of cells with DNA content below the threshold for cells in 
G1, following 18 h treatment with 1.5, 15 or 150 µM etoposide. Data 
shown are mean + SD from seven independent experiments with 
three replicates each. b MEFs were treated with 1.5, 15 or 150 µM 
etoposide for 3, 6 or 18 h. Con indicates extract from untreated cells. 
Total cell proteins were probed with anti‑Caspase‑3 antibody. Vinculin 
was used as the loading control. Figures are representative of three 
independent experiments showing similar results. Fig. 2 Etoposide effect on p53‑mediated transcriptional events. a 
MEFs were treated with 15 µM of etoposide (upper panel) or 1.5 µM 
of etoposide (lower panel) for 1, 3, 6 or 18 h. Total cell proteins were 
probed with anti‑PUMA antibody. Vinculin or actin was used as 
the loading control. b MEFS were treated with 15 µM of etoposide 
(upper panel) or 1.5 µM of etoposide (lower panel) for 30 min, 1, 3, 6 or 
18 h. Total RNA was isolated and reverse transcribed into cDNA. The 
expression of p21CIP1/WAF1 was determined by RT‑PCR using specific 
primers. β‑actin was used a loading control. Figures are representative 
of three independent experiments.
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PFT-α in inhibiting the transcriptional up-regulation 
of p21CIP1/WAF1 gene expression. MEFs were pre-treated 
with PFT-α followed by addition of 15  µM etoposide 
for various time periods. PFT-α effectively inhibited 
the up-regulation in p21CIP1/WAF1 for up to 6 h (Fig. 3b), 
suggesting that the drug was indeed effective in suppress-
ing p53-regulated transcription. However, it failed to do 
so in cells that were treated for 18 h, a result that may be 
explained based on studies showing that the half-life of 
PFT-α is approximately 5  h in physiological conditions 
Fig. 3 Effect of PFT‑α on etoposide‑induced apoptosis. a MEFs, pre‑treated with 30 μM PFT‑α followed by 18 h treatment with 1.5, 15 or 150 µM 
etoposide, were analyzed by flow cytometry to determine percentage of cells having sub‑G1 DNA content. Cells were treated in parallel with UVC 
and analyzed after 18 h. Control indicates normally proliferating cells. Columns represent percentage of cells having sub‑G1 DNA content, as ana‑
lyzed by flow cytometry. Data are mean + SD of three independent experiments with three replicates each. b mRNA was extracted from untreated 
(0 h), 6 and 18 h treatment with 15 µM of etoposide (black bars) or pre‑treatment with PFT‑α followed by etoposide (open bars). The relative expres‑
sion of p21cip1/waf1 was determined by qRT‑PCR (mean ± SD from three independent experiments). The values of p21cip1/waf1 were normalized to 
β‑actin. c, d Parallel studies used 1.5 or 15 µM etoposide. Sub‑G1 population of MEFs was measured as in A for cells that were untreated (Control), 
pre‑treated with 30 μM PFT‑α followed by etoposide for 3 h (PFT‑α‑Etop 3 h), etoposide alone for 19 h (Etop 19 h), pre‑treated with PFT‑α followed 
by etoposide for 19 h (PFT‑α‑Etop 19 h), washed after 3 h of co‑treatment, followed by further incubation for 18 h (PFT‑α‑Etop washed) and washed 
after 3 h, and PFT‑α was added back for 18 h (PFT‑α‑Etop + PFT‑α). Columns represent percentage of cells having sub‑G1 DNA content; representa‑
tive of three experiments with similar results.
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[25]. We can conclude that blocking p53-dependent tran-
scriptional events does not affect etoposide-induced cell 
death.
In another experimental approach, cells were incu-
bated with PFT-α and subsequently treated with etopo-
side for 18 h, or treated with PFT-α and etoposide for 3 h 
only, and the drug washed out prior to incubation in the 
presence or absence of PFT-α for 18  h. Cell death was 
assessed by measurement of sub-G1 DNA content. While 
no death is detected after 3 h of etoposide treatment (not 
shown), 3  h treatment with either 1.5 or 15 μM etopo-
side, followed by washing and further incubation, was 
sufficient to induce cell death, almost as well as continual 
exposure to etoposide. However, this was not affected 
by the presence of PFT-α, despite its ability to block 
p53-mediated transcription (Fig.  3b–d). Together, these 
experiments support the conclusion that etoposide-
induced cell death is not due to an effect on p53-depend-
ent transcription.
PES inhibits etoposide–induced apoptosis and cell cycle 
checkpoint response
Since we had shown that etoposide-induced cell death 
is independent of p53’s transcriptional regulation, we 
tested the effect of pre-treatment with 10 µM PES. PES 
is a small molecule that prevents the association of p53 to 
the mitochondria [13, 26]. Western blot analysis of mito-
chondrial extracts following etoposide treatment showed 
a dramatic increase in mitochondrial p53 abundance, 
which was blocked in PES-treated cells (data not shown). 
To directly assess the effect of PES on p53’s interaction 
with a known binding partner at the mitochondria, p53 
was immunoprecipitated and the immunoprecipitate was 
probed for BCL-xL levels. As shown in Fig. 4a, PES dis-
rupted the p53/BCL-xL interaction. It should be noted 
that PES had little to no effect on total cellular p53 lev-
els (see other data below). Furthermore, pre-treatment of 
MEFs with PES dramatically inhibited etoposide-induced 
generation of sub-G1 DNA content, particularly at ear-
lier times (Fig. 4b). Moreover, PES was able to effectively 
block death of cells that were treated with a 10–100 fold 
higher concentration of etoposide over a period of 18 h, 
as well as cell death induced by UVC treatment (Fig. 4c). 
Together, this provides further evidence that the primary 
means by which etoposide induces cell death is via the 
transcription-independent functions of p53.
The transcription independent death pathway of p53 
has been suggested to occur via several possible path-
ways: p53 may act as a ‘super’ BH3-only protein and may 
interact with the multi domain anti-apoptotic BCL-2 
family members to liberate pro-apoptotic members from 
inhibitory complexes [27–29] or p53 can interact directly 
with pro-apoptotic BAK to release cytochrome C [29]. 
Yet another model proposed that stress-induced cyto-
solic p53 is sequestered by soluble anti-apoptotic BCL-XL 
and transcriptional activation of PUMA displaces p53, 
which then activates monomeric cytosolic BAX to induce 
apoptosis [10]. Our results showing that activation of 
PUMA was not required are not consistent with the lat-
ter possibility, and likely support a role for p53 as a BH3-
only protein at the mitochondria.
We next investigated the cell cycle status of the MEFs 
in the various treatment conditions. Our results showed 
that in response to treatment with etoposide, MEFs 
undergo a DNA damage-induced arrest at the G2/M 
phase of the cell cycle and apoptotic cells with sub-G1 
levels of DNA can be detected, as expected (Fig.  5a). 
Interestingly, while PFT-α had no effect, treatment of 
cells with PES overrides the etoposide-induced DNA 
damage checkpoint at G2/M (Fig. 5a, b). Similar results 
were obtained when HeLa cells were pre-treated with 
PES and followed by treatment with etoposide (data 
not shown). Etoposide is known to activate checkpoint 
response, which delays the progression through the 
cell cycle. Since the progression of cell cycle from G2 
to mitosis is driven by cyclin dependent kinase CDK1 
[30], it is a prime target of DNA damage response pro-
teins for instigation of G2/M arrest. The CDK inhibitor 
p21CIP1/WAF1 has been shown to be up-regulated at both 
G1/S and G2/M checkpoints and studies of Ding et  al. 
have reported an increase in its expression in response 
to etoposide treatment in a p53-dependent manner [31]. 
We therefore determined whether the ability of PES to 
alter cell cycle effects of etoposide is due to any effect on 
down-regulation of p21CIP1/WAF1 expression. As seen in 
Fig. 5c, PES treatment had no apparent effect on etopo-
side-induced p21CIP1/WAF1 transcription. Again, this find-
ing supports the suggestion that etoposide’s effects are 
mediated largely through p53’s functions at the mito-
chondria, unrelated to transcriptional regulation.
We next investigated the effect of PES treatment on 
CDK1/Cyclin B1 activity. Phosphorylation of CDK1 at 
the inhibitory site, Tyr15, is a key event controlling the 
G2/M switch. MEFs were treated with either etopo-
side alone or in combination with PES for 3 or 6 h and 
expression of phospho-Tyr15-CDK1 was investigated 
by immunoblotting. As shown in Fig. 5d, an increase in 
phospho-Tyr15-CDK1 was observed at 3 and 6  h post 
treatment with etoposide, as expected in cells blocked at 
G2/M. Pre-treatment with PES decreased the etoposide-
induced CDK1 phosphorylation at both 3 and 6  h. We 
next examined the effect of PES on Cyclin B1 expres-
sion, which is an absolute requirement for CDK1 activity. 
Similar to phospho-Tyr15-CDK1, an increase in Cyclin 
B1 expression was observed at 3 and 6 h post-etoposide 
treatment. Interestingly, the Cyclin B1 level was much 
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lower in the presence of PES. A decrease in phospho-
Tyr15-CDK1/Cyclin B1 expression is consistent with 
cells escaping the G2 checkpoint arrest that normally 
occurs in response to etoposide treatment. Activation of 
Checkpoint kinase 1 (CHK1) blocks the entry into mito-
sis by phosphorylating members of CDC25 family of 
phosphatases, which activate cyclin B1-CDK1 through 
dephosphorylation of Thr14 and Tyr15 [32, 33]. Hence, 
we next examined whether the inhibitory effect of PES 
on Tyr15-CDK1 was the consequence of CHK1 inhibi-
tion. We probed the same membrane with anti-phos-
pho-Ser345 CHK1 antibody. Our results showed that, as 
expected, CHK1 was activated in response to etoposide 
treatment at 3 and 6 h. Pre-treatment with PES resulted 
in a marked reduction in CHK1 activation which would 
eventually impede the cell cycle arrest by allowing the 
cells to enter mitosis. These results highlight several pos-
sible mechanisms by which PES treatment is overriding 
the etoposide-induced cell cycle arrest.
Treatment with etoposide causes G2 arrest by 
p53-dependent and independent pathways and either 
pathway can adequately cause G2 arrest [16]. The 
p53-dependent pathway can exert its inhibitory effects 
on cell cycle progression through either direct binding 
of p21cip1/waf1 to CDK1 [34], down-regulation of CDK1/
Cyclin B1 protein levels [16] or p21cip1/waf1 mediated pre-
vention of inhibitory phosphorylation of P130 and P107 
by CDKs, which in turn represses the transcription of 
Fig. 4 Effect of PES on etoposide‑induced cell death. a MEFs were either untreated (Con) or treated with etoposide (Etop) for 6 h, or pre‑treated 
with 10 μM of PES followed by 1.5 μM of etoposide for 6 h. Mitochondrial extracts were immunoprecipitated with anti‑p53 antibody and probed 
for Bcl‑xL. The first lane (IP Con IgG) represents mitochondrial extracts from untreated (Con) cells immunoprecipitated with rabbit IgG alone Input 
p53 represents the starting material unbound to the Agarose G beads, probed for the presence of p53. b MEFs were treated with either 1.5 µM 
etoposide alone or pre‑treated with 10 μM of PES and followed by 1.5 µM etoposide for various times. Columns represent percentage of cells 
having sub‑G1 DNA content. A one‑way ANOVA was carried out to compare the treatment groups. Post hoc comparison using the Tukey HSD test 
indicated significant inhibitory effect of PES treatment on the percentage of cells having sub‑G1 DNA content. Data shown are mean + SD from 3 
independent experiments with three replicates each. c Analysis of MEFs was done as in B; cells were pre‑treated with 10 μM PES followed by 18 h 
treatment with 1.5, 15 or 150 µM etoposide. Cells were treated in parallel with UVC and followed for 18 h. Statistical analysis was as in b. Data are 
mean + SD of three repeat analyses.
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several genes required for progression through G2/M 
[35]. The p53-independent pathway on the other hand 
is regulated by DNA damage response kinases ATM 
and ATR [36]. Our results showed that in response to 
treatment with 1.5  µM of etoposide, the cells arrest at 
G2 through the p53-independent pathway and that PES 
is able to bypass it by inhibiting the phosphorylation of 
CHK1 on Ser 345 (Fig.  5d). These data contradict the 
findings of Balaburski et al. who showed that PES treat-
ment leads to G2/M arrest by inhibiting the activity of 
Anaphase promoting complex/cyclosome and thus pre-
vents the degradation of Cyclin B1 [37]. The reason for 
this apparent discrepancy is not clear as Balaburski et al. 
used HeLa cells in their studies and we have also con-
firmed that our results, first observed in MEFs, are also 
observed in HeLa cells.
PES enhances deacetylation of Lys373/382 of p53
The stability and activity of p53 is regulated by post-
translational modifications [38]. In particular, acetylation 
of lysine residues in the C-terminal regulatory domain of 
p53 has been shown to correlate well with the stability 
and activity of p53 [39]. We examined the effect of PES on 
the acetylation of Lys 373/382 of p53. Since MEFs used in 
the study were transformed using SV40 large T antigen, 
the p53 is constitutively acetylated at Lys 373/382. Inter-
estingly when cells were treated with either PFT-α or PES 
alone, a decrease in Lys 373/382 acetylation of p53 was 
observed (data not shown). However, treatment of MEFs 
with PFT-α was unable to exert any effect on p53 acetyla-
tion when added with etoposide, while PES added in the 
presence of etoposide resulted in reduced acetylation on 
residues 373 and 382 (Fig. 6a).
PES mediated deacetylation of p53 is not regulated 
by Mdm2‑HDAC1
Mdm2 has been shown to negatively regulate acetylation 
of p53 [38, 40]. The effect of Mdm2 on p53 acetylation 
was reported to result following recruitment of a com-
plex containing Histone deacetylase 1 (HDAC1) [41]. We 
therefore sought to determine whether p53 in normally 
proliferating MEFs was bound to Mdm2 and whether 
Fig. 5 Effect of PES on cell cycle events. a Representative flow cytometry profiles of MEFs, with control (no treatment), treatment with 1.5 µM 
etoposide for 18 h, pre‑treatment with 30 μM of PFT‑α followed by 18 h treatment with 1.5 µM etoposide or pre‑treatment with 10 μM of PES 
followed by 18 h treatment with 1.5 µM etoposide. Percentage of cells having sub‑G1 DNA content is indicated. Data shown are representative of 
six experiments with similar results. b Columns represent distribution of cells in G1, S and G2/M phases of cell cycle, as analyzed by flow cytometry. 
Data are mean + SD of three independent experiments with three replicates each. c MEFs were treated for various times with 15 µM of etopo‑
side either alone or pre‑treated with 10 μM of PES. Total RNA was isolated and reverse transcribed into cDNA. The expression of p21cip1/waf1 was 
determined using specific primers in RT‑PCR. β‑actin was used as a loading control. Representative of three independent experiments. d MEFs were 
untreated (Con) or treated with 1.5 µM of etoposide for 3 or 6 h alone or pre‑treated with 10 μM PES. Total cell proteins were probed with anti‑
Ser345 CHK1, anti‑CHK1, anti‑phospho‑Tyr 15 CDK1, anti‑CDK1, Cyclin B1 antibodies, and anti‑vinculin as the loading control.
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treatment with PES would enhance recruitment of 
Mdm2-HDAC1 complex. We used co-immunoprecipita-
tion studies to determine these interactions. Our results 
showed that in untreated MEF cells, p53 interacts with 
both endogenous Mdm2 as well as HDAC1. However, 
pre-treatment of cells with either PFT-α or PES resulted 
in an increase in Mdm2-independent p53/HDAC1 asso-
ciation. We did not observe an effect on the HDAC1 
association upon treatment with etoposide alone. It 
is noteworthy that despite recruitment of HDAC1 to 
p53 in PFT-α treated MEFs, no deacetylation of p53 on 
Lys373/382 is observed in cells co-treated with etoposide 
(Fig. 6a, b) suggesting that presence of HDAC1 alone may 
not be sufficient for deacetylation.
p53 is transiently activated and stabilized in response 
to various stimuli by post-translational modifications. 
These modifications include phosphorylation [42], which 
has been shown to interfere with the ability of Mdm2 
to negatively regulate p53 [43] and acetylation, which 
has been shown to promote p53 stability [41]. It is well 
established that Mdm2 ubiquitinates p53 on lysine resi-
dues 373/382 and hence acetylation of these residues 
prevents the ubiquitin mediated turnover of p53 [38, 
42]. Therefore, our finding that p53 is associated with 
Mdm2 and HDAC1 in MEFs that normally express p53 
acetylated on Lysine 373/382 residues are intriguing. One 
explanation for these observations could be that the pres-
ence of another protein partner is required in the com-
plex for efficient deacetylation. The pre-treatment with 
either PFT-α or PES, which affect p53 very differently, 
both caused increased recruitment of HDAC1 to p53. 
In this context it should be mentioned that recruitment 
of HDAC1 is Mdm2 independent and while PES causes 
deacetylation in the presence or absence of etoposide 
treatment, PFT-α deacetylates only when added alone. 
Etoposide and small molecule inhibitors PFT-α and PES 
have distinct activities related to their effects on p53 
and perhaps the composition of the complex formed is a 
reflection of that. These observations are indeed intrigu-
ing and necessitate further investigation.
Conclusion
Despite decades of study in numerous experimental 
systems, the pathways by which p53 is regulated follow-
ing treatment with etoposide, a commonly used drug 
for chemotherapy and a potent inducer of DNA dam-
age, remain incompletely characterized. In this study, we 
asked whether etoposide induced cell death via p53 tran-
scription-dependent events, or whether the mitochon-
drial events targeted by p53 were involved. Our first hint 
that transcription-dependent regulation by p53 is not 
required came from observations in which lower concen-
trations of etoposide were used. While the low concentra-
tion of etoposide was able to induce substantial cell death, 
it had no detectable effect on p53-dependent transcrip-
tion. We next used known inhibitors of p53, PFT-α and 
PES, which target p53 transcriptional and mitochondrial 
functions, respectively. These compounds have both been 
reported to suppress death in mice exposed to radiation, 
and could thus be useful to block the harmful effects of 
chemotherapy that occur via p53-induced death. In our 
studies, PFT-α was able to suppress p53-mediated tran-
scription induced by etoposide treatment. However, it 
was unable to suppress cell death induced by either low 
or high concentrations of etoposide. These results suggest 
that PFT-α cannot effectively block etoposide-induced 
death, despite blocking the induction of transcription 
via p53. On the other hand, PES was very effective in 
blocking etoposide-induced cell death, as determined by 
its ability to block the appearance of sub-G1 DNA con-
tent. We showed that PES may act in multiple ways to 
bypass the effects of etoposide, including (1) a dramatic 
effect in blocking etoposide-induced association of p53 
Fig. 6 Effect of drugs on p53 acetylation and complex formation. 
a MEFs were either left untreated (Con) or treated with etoposide 
(Etop) alone or in combination with either PFT‑α or PES for 3 h. 
Total cell extracts were prepared. The blot was probed with anti‑
Lys373/382 p53 antibody or anti‑p53 as a loading control. b MEFs 
were either untreated (Con) or treated with etoposide (Etop) for 3 h, 
or pre‑treated with either 30 µM of PFT‑α or 10 μM of PES followed by 
1.5 μM of etoposide for 3 h. Total cell extracts were immunoprecipi‑
tated with anti‑p53 antibody and probed for HDAC1 and Mdm2. The 
first lane (IP Con IgG) represents PES and etoposide‑treated extracts 
immunoprecipitated with rabbit IgG alone to indicate position of the 
IgG heavy chain (IgGH). Input Mdm2 represents the starting material 
unbound to the Agarose G beads, probed for the presence of Mdm2.
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with the mitochondria (without any major effect on p53 
total expression, (2) blocking the G2/M arrest induced by 
etoposide, likely via effects on Cyclin B1/CDK1, and (3) 
blocking acetylation of p53.
The in  vivo relevance of the mitochondrial effects of 
p53 is emphasized by the observation that within 30 min 
of radiation or injection of a clinical dose of etoposide in 
drug sensitive organs, activation of caspase-3 is observed, 
and this precedes detectable p53 dependent gene activa-
tion [44]. The significance of this observation has been 
underscored further by our observation that cell death 
still ensues when p53-dependent transcription is blocked 
for the duration of DNA damage. Based on these obser-
vations and those of others [45], we would like to stress 
that the p53 mitochondrial pathway is pivotal in exert-
ing the lethal effects of chemo-/radiotherapy observed in 
sensitive cells.
In conclusion, our observation that a low, but clini-
cally pertinent, concentration of etoposide is able to elicit 
death of cells whose p53 transcription function has been 
blocked has implications for use of etoposide in combina-
tion with chemotherapeutic agents that block transcrip-
tion (reviewed by Ljungman and Lane [46]) or in tumors 
with mutations in the p53 DNA-binding core domain. 
To provide a fail-safe mechanism of eliminating cancer-
ous cells, efforts could focus on enhancing the effects of 
p53 in causing cell death via its effects at the mitochon-
dria. At the very least, our work supports effects to com-
bine etoposide treatment in p53-inactive tumours, with 
agents that induce apoptosis via mitochondrial pathways 
dependent on BCL-2 family members.
Methods
Cell lines
Wild type MEFs (a kind gift from Dr. J. Opferman) were 
obtained from mixed 129/B6 background embryos har-
vested on E10.5. The primary P3 cells were immortalized 
by SV40 and cloned. Single cell clones were cultured in 
DMEM supplemented with 10% fetal bovine serum.
Antibodies and reagents
Normal rabbit IgG and anti-actin (I-19) were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
Monoclonal anti-human vinculin was purchased from 
Sigma-Aldrich (Oakville, ON, USA). Rabbit anti-phos-
pho-Tyr15 CDK1, rabbit anti-phospho-Ser345 CHK1, 
Bcl-xL and anti-caspase-3 antibodies were from Cell 
Signaling Technology (Beverly, MA, USA). Anti-CHK1 
(D-7) and anti-cyclin B1 (H 433) were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rab-
bit polyclonal p53 antibody (CM5) was from Leica 
Microsystems (Concord, ON, USA), anti-acetyl-p53 (Lys 
373, Lys 382) was from Millipore (Billerica, MA, USA) 
and anti-COX IV was from Abcam (Toronto, ON, USA). 
Etoposide, PFT-α and PES were purchased from Calbio-
chem (La Jolla, CA, USA). Fetal bovine serum and Pro-
tein-G Agarose beads were purchased from Invitrogen 
(Carlsbad, CA, USA).
Cell treatments
The stock solutions of etoposide, PFT-α and PES were 
prepared in DMSO. An equal amount of DMSO was 
added to the control cells in each experiment. MEFs 
were treated with 1.5, 15 or 150 µM of etoposide for indi-
cated periods of time. Pre-treatments with PFT-α or PES 
were carried out by incubation of cells with either 30 µM 
of PFT-α or 10 µM of PES for 10 min prior to the addi-
tion of etoposide. The UV irradiation was performed by 
removal of medium, washing once with PBS and expo-
sure to a controlled dose of UVC (254 nm) light using an 
UltraLum cross-linker (Claremont, CA, USA).
Immunoblotting
Cells were washed with PBS and suspended in ice-cold 
solubilization buffer (20 mM Tris HCL pH 8.0, 1% NP40, 
10% glycerol, 137  mM NaCl, 10  mM NaF, with Roche 
protease inhibitor cocktail) then sonicated for 5 s before 
centrifugation at 32,000×g for 5 min. Equivalent concen-
trations of protein were resolved using SDS–polyacryla-
mide gel electrophoresis and transferred to nitrocellulose 
membranes. Membranes were blocked for 1 h in TBST-
5% low-fat milk followed by overnight incubation at 4°C 
with appropriate antibody and detection of IR-conju-
gated secondary antibodies using a LiCor Odyssey. The 
mitochondrial extracts were prepared by using mito-
chondria isolation kit for cultured cells (Thermo Scien-
tific) according to the manufacturer’s recommendations.
Immunoprecipitation
For immunoprecipitation of p53 complexes, total cell 
extracts were pre-cleared with 20 μl of Protein G agarose 
beads for 30 min. One μg/ml anti-p53, or normal rabbit 
IgG antibody was added and after an overnight incuba-
tion, the immunoprecipitates were collected by adding 
50  μl of Protein G agarose beads. Beads were washed 
four times with solubilization buffer.
RT‑PCR and quantitative real‑time PCR
Total RNA was isolated from these cells using the Gene-
Jet RNA purification kit (Thermo Scientific) according 
to the manufacturer’s recommendations. Total RNA 
was reverse transcribed into cDNA using the Rever-
tAid H minus reverse transcriptase (Thermo Scientific). 
The expression of p21CIP1/WAF1 was determined by RT-
PCR using specific primers (sequence described below). 
β-actin was used a loading control.
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For real-time PCR, amplification was performed using 
LightCyclerFastStart DNA Master Plus SYBR (Roche 
Applied Science, Mannheim, Germany) and using the 
comparative cycle threshold method (2−∆∆CT) to quantify 
gene expression. The mRNA levels were normalized to 
mouse β-actin expression (sense primer: 5′-GAGCACAG 
CTTCTTTGCAGCT-3′ and antisense primer: 5′-CCCAC 
ATAGGAGTCCTTCTAGCC-3′). The primer sequences 
for the p21 were 5′-GTGTGCCGTTGTCTCTTCGG-3′ 
and 5′-CTCAGGTAGACCTTGGGCAG-3′.
Flow cytometry for cell cycle and subdiploid DNA staining
Cells for flow cytometric analysis were fixed in 70% (v/v) 
ethanol. The cells were subsequently stained in PBS con-
taining 50  μg/ml of PI (propidium iodide), 100  μg of 
RNase A and 0.1% glucose. Cells were analysed using BD 
FACSCanto II (BD Biosciences, San Jose, CA, USA).
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